Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2023-07-17 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - ANP 5 pages 28.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It details the number of securities to be issued, the issue price, the proposed issue date, and other related information such as fees and the purpose of the issue. The document does not contain financial statements or detailed financial analysis but is focused on informing about a capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length and content confirm it is not merely a brief notice or a report publication announcement but a substantive announcement about a financing event.
2023-07-17 English
Trading Halt 2 pages 567.5KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement regarding a trading halt requested by Antisense Therapeutics Limited (ASX: ANP). The halt is pending an announcement related to a capital raising. The text references ASX Listing Rule 17.1 and explicitly states the halt is to allow a proposed capital raising to take place in an orderly fashion. There is no financial data, report, or detailed analysis present. The document is short (2594 characters) and serves as a notification of a trading halt rather than a report or detailed announcement of the capital raising itself. According to the classification rules, this type of document fits best under Capital/Financing Update (CAP) because it relates to financing activities and capital structure changes, even though it is a preliminary announcement about a trading halt pending a capital raising announcement. It is not a full report or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2023-07-13 English
MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 June 2023, reporting that Antisense Therapeutics Limited has received regulatory approvals to conduct a Phase IIb clinical trial in the UK and other countries. It provides updates on trial progress, patient dosing, and upcoming presentations. The content is a regulatory and operational update about clinical trial approvals and progress, not a financial report, earnings release, or management discussion. It is a typical regulatory announcement informing the market about a significant development in the company's drug development program. The document length is 3614 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial statements, detailed financial data, or management analysis. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2023-06-26 English
First Patient Dosed in ATL1102 Phase IIb DMD Trial 2 pages 104.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 June 2023 about the commencement of patient dosing in a Phase IIb clinical trial for ATL1102 in Duchenne Muscular Dystrophy. It provides details about the trial design, sites, regulatory approvals, and future expectations. There are no financial statements, earnings data, or detailed management analysis. The document is a corporate announcement about a clinical trial milestone, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial start, not just a notice of report availability. The content fits best as a general regulatory announcement about company progress and clinical development updates, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-06-07 English
Shareholder Newsletter 4 pages 156.2KB
Management Reports Classification · 90% confidence The document is a shareholder newsletter dated June 2023 from Antisense Therapeutics. It provides detailed updates on clinical development progress, leadership changes, regulatory approvals, and strategic plans. It is addressed to shareholders and discusses ongoing clinical trials, team changes, and future outlook. The document is about 15,000 characters long, indicating it is a substantive communication rather than a brief announcement. It does not contain formal financial statements or quarterly/yearly financial results, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, audit report, or legal proceeding update. It is not a proxy solicitation or voting results announcement. The content focuses on company progress, management commentary, and strategic updates to shareholders, which aligns with a Management Report (MDA) or possibly an Investor Presentation (IP). However, it is presented as a newsletter letter rather than a formal presentation slide deck. Given the detailed management discussion and outlook provided, the best fit is Management Reports (MDA).
2023-06-05 English
Final Director's Interest Notice 2 pages 279.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of a director who has ceased to be a director, including ordinary shares and unlisted options. There is no financial performance data, earnings information, or management discussion. The content is focused on the personal share transactions and holdings of a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming it is not a broader financial or regulatory report.
2023-05-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.